Driving Drug Development for Hematologic Diseases

Relationships That Fuel Research

Our mobile, direct-to-patient approach gives you access to the difficult-to-reach populations affected by these debilitating disorders. You’ll get an all-inclusive view of each patient in your study-meaning you’ll collect more accurate data points related to the complex differences seen on an individual level. Moreover, Sanguine’s emphasis on establishing trust ensures long-term patient participation and study completion.

  • Amyloidosis
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Sickle Cell Disease (SCD)
  • Thrombotic Thrombocytopenic Purpura (TTP)

Sanguine's Expertise in Hematology


Patient Members


Studies Completed


Contact us to discuss your research needs

Sanguine Services

  • Whole Blood
  • Serum
  • Plasma
  • PBMCs (+ Derivatives)
  • Buffy Coat
  • PBMC isolation
  • Serum and plasma isolation
  • T cell isolation
  • B cell isolation
  • Natural killer cell isolation
  • Genotype
  • Blood Type
  • Family History
  • Hospitalization status
  • No treatment
  • Disease Confirmation
  • Covid-19 (PCR)
  • Sickle Cell
  • HIV/HPV/Hepatitis/Herpes Etc.
  • BioMarker Quantification
  • CBC, Platelett, & Diff
  • CRP
  • Cal-Protecin
  • ANA
  • Cytokine Panel
  • BUN
  • Urinalysis
  • Thyroid Stimulating Hormone
  • Lipid Panel
  • LDH
  • Genetic Analysis
  • HLA Typing
  • dsDNA
  • RNA Vial Load Qaunitification
  • HBV Genotyping
  • Vaso-occlusive crisis (VOC) events (Sickle cell disease)
  • Longitudinal
  • Sickle cell disease studies - exclude disease-modifying therapies

Patient-Led Biospecimen and Data Collection: A New Frontier in Sickle Cell Research


Forging a Path for Early Clinical Development in Sickle Cell Disease

Hear From Our Community


"My journey with Sanguine has been very optimistic. Whenever I get a call about a possible sickle cell disease study, I feel compelled to do it. Knowing that my participation helps with developing innovative safe treatments, and possibly a cure, I look it at as my being a superhero for our future generation. We’re more than a ‘subject’!"